Overview

ENX-102 Phase 2 Social Anxiety Disorder

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
Phase:
PHASE2
Details
Lead Sponsor:
Engrail Therapeutics INC